

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
16 September 2004 (16.09.2004)

PCT

(10) International Publication Number
WO 2004/078718 A1

(51) International Patent Classification⁷: **C07D 207/26**,
207/38, A61K 31/40

(74) Agent: **KONDO, Rie**; GlaxoSmithkline, CIP (CN925.1),
980 Great West Road, Brentford, Middlesex TW8 9GS
(GB).

(21) International Application Number:
PCT/EP2004/001843

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(22) International Filing Date: 24 February 2004 (24.02.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0305024.2 5 March 2003 (05.03.2003) GB

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Euro-
pean (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,
GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **GLAXO
GROUP LIMITED** [GB/GB]; Glaxo Wellcome House,
Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): **DAMIANI, Fed-
ERICA** [IT/IT]; GlaxoSmithkline, Via Alessandro Fleming
2, I-37135 Verona (IT). **HAMPRECHT, Dieter** [DE/IT];
GlaxoSmithkline, Via Alessandro Fleming 2, I-37135
Verona (IT). **MICHEL, Fabrizio** [IT/IT]; GlaxoSmithk-
line, Via Alessandro Fleming 2, I-37135 Verona (IT).
PASQUARELLO, Alessandra [IT/IT]; GlaxoSmithk-
line, Via Alessandro Fleming 2, I-37135 Verona (IT).
TEDESCO, Giovanna [IT/IT]; GlaxoSmithkline, Via
Alessandro Fleming 2, I-37135 Verona (IT).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: COMPOUNDS HAVING ACTIVITY AT 5HT_{2C} RECEPTOR AND USES THEREOF




(57) Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof are disclosed, wherein R_1 is hydrogen, fluoro, chloro, hydroxy, C_{1-6} alkyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkyloxy, C_{1-6} alkoxy or halo C_{1-6} alkoxy; m is 0 when $====$ is a double bond and m is 1 when $====$ is a single bond; R_2 is hydrogen, halogen, cyano, nitro, C_{1-6} alkyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkyloxy, halo C_{1-6} alkyl, C_{1-6} alkoxy, halo C_{1-6} alkoxy, C_{1-6} alkylthio, amino, mono- or di- C_{1-6} alkylamino or an N-linked 4 to 7 membered heterocyclic group; X is $-(CH_2-CH_2)-$, $-(CH=CH)-$, $-(CH_2)_3-$, $-C(CH_3)_2-$, $-(CH=CH-CH_2)-$, $-(CH_2-CH=CH)-$ or a group $-(CHR_5)-$ wherein R_5 is hydrogen, halogen, hydroxy, cyano, nitro, C_{1-6} alkyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkyloxy, halo C_{1-6} alkyl, C_{1-6} alkoxy, halo C_{1-6} alkoxy or C_{1-6} alkylthio; R_3 is halogen, cyano, C_{1-6} alkyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkyloxy, C_{1-6} alkoxy, C_{1-6} alkylthio, hydroxy, amino, mono- or di- C_{1-6} alkylamino, an N-linked 4 to 7 membered heterocyclic group, nitro, halo C_{1-6} alkyl, halo C_{1-6} alkoxy, aryl, aryl C_{1-6} alkyl, aryl C_{1-6} alkyloxy, aryl C_{1-6} alkylthio or $COOR_6$, $CONR_7R_8$ or COR_9 wherein R_6 , R_7 , R_8 and R_9 are independently hydrogen or C_{1-6} alkyl; p is 0, 1 or 2 or 3; R_4 is hydrogen, halogen, hydroxy, cyano, nitro, C_{1-6} alkyl, C_{1-6} alkanoyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkyloxy, halo C_{1-6} alkyl, C_{1-6} alkoxy, halo C_{1-6} alkoxy, C_{1-6} alkylthio, amino, mono- or di- C_{1-6} alkylamino or an N-linked 4 to 7 membered heterocyclic group; Y is oxygen, sulfur, $-CH_2-$ or NR_{10} wherein R_{10} is hydrogen or C_{1-6} alkyl; D is a single bond, $-CH_2-$, $-(CH_2)_2-$ or $-CH=CH-$; and Z is $-NR_{11}R_{12}$ where R_{11} and R_{12} are independently hydrogen or C_{1-6} alkyl, or an optionally substituted N-linked or C-linked 4 to 7 membered heterocyclic group. Method of preparation and uses of the compounds in therapy, for example depression and anxiety, are also disclosed.

Compounds having activity at 5HT_{2c} receptor and uses thereof

This invention relates to novel compounds having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of CNS and other disorders.

WO 96/23783, WO 97/46699 and WO 97/48700 all disclose a series of indoline derivatives which are 5-HT_{2C} receptor antagonists and which are claimed to be useful in the treatment of various CNS disorders.

A novel class of compounds possessing 5-HT_{2C} receptor activity has been found. The present invention therefore provides, in a first aspect, a compound of formula (I) or a pharmaceutically acceptable salt thereof:



wherein:

- 15 R_1 is hydrogen, fluoro, chloro, hydroxy, C₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyloxy, C₁₋₆alkoxy or haloC₁₋₆alkoxy;
m is 0 when $\text{---}=\text{---}$ is a double bond and m is 1 when $\text{---}=\text{---}$ is a single bond;
- R_2 is hydrogen, halogen, cyano, nitro, C₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyloxy, haloC₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkoxy, C₁₋₆alkylthio, amino, mono- or
- 20 di-C₁₋₆alkylamino or an N-linked 4 to 7 membered heterocyclic group;
X is $\text{---}(\text{CH}_2\text{---CH}_2)\text{---}$, $\text{---}(\text{CH}=\text{CH})\text{---}$, $\text{---}(\text{CH}_2)_3\text{---}$, $\text{---}\text{C}(\text{CH}_3)_2\text{---}$, $\text{---}(\text{CH}=\text{CH}\text{---CH}_2)\text{---}$, $\text{---}(\text{CH}_2\text{---CH}=\text{CH})\text{---}$ or a group $\text{---}(\text{CHR}_5)\text{---}$ wherein R_5 is hydrogen, halogen, hydroxy, cyano, nitro, C₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyloxy, haloC₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkoxy or C₁₋₆alkylthio;
- 25 R_3 is halogen, cyano, C₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyloxy, C₁₋₆alkoxy, C₁₋₆alkylthio, hydroxy, amino, mono- or di-C₁₋₆alkylamino, an N-linked 4 to 7 membered heterocyclic group, nitro, haloC₁₋₆alkyl, haloC₁₋₆alkoxy, aryl, arylC₁₋₆alkyl, arylC₁₋₆alkyloxy, arylC₁₋₆alkylthio or COOR₆, CONR₇R₈ or COR₉ wherein R₆, R₇, R₈ and R₉ are independently hydrogen or C₁₋₆alkyl;
- 30 p is 0, 1 or 2 or 3;
- R_4 is hydrogen, halogen, hydroxy, cyano, nitro, C₁₋₆alkyl, C₁₋₆alkanoyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyloxy, haloC₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkoxy, C₁₋₆alkylthio, amino, mono- or di-C₁₋₆alkylamino or an N-linked 4 to 7 membered heterocyclic group;
- Y is oxygen, sulfur, $\text{---CH}_2\text{---}$ or NR₁₀ wherein R₁₀ is hydrogen or C₁₋₆alkyl;
- 35 D is a single bond, $\text{---CH}_2\text{---}$, $\text{---}(\text{CH}_2)_2\text{---}$ or $\text{---CH}=\text{CH}\text{---}$; and

Z is $-NR_{11}R_{12}$ where R_{11} and R_{12} are independently hydrogen or C_{1-6} alkyl, or an optionally substituted N-linked or C-linked 4 to 7 membered heterocyclic group.

5 The following terms, whether used alone or as part of another group are to be given the following meanings, unless otherwise stated.

The term "halogen" and its abbreviated form "halo" are used herein to describe fluorine, chlorine, bromine or iodine.

10 The term "alkyl" is used herein to describe a straight chain or branched fully saturated hydrocarbon group. " C_{1-6} alkyl" refers to alkyl groups having from one to six carbon atoms, including all isomeric forms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, neopentyl, sec-pentyl, n-pentyl, isopentyl, tert-pentyl and hexyl.

15 The term " C_{1-6} alkanoyl" refers to an alkanoyl group having from 1 to 6 carbon atoms, such as methanoyl (or "formyl"), ethanoyl (or "acetyl"), propanoyl, isopropanoyl, butanoyl, isobutanoyl, sec-butanoyl, pentanoyl, neopentanoyl, sec-pentanoyl, isopentanoyl, tertpentanoyl and hexanoyl.

20 The term " C_{1-6} alkoxy" refers to a straight chain or branched chain alkoxy (or "alkyloxy") group having from one to six carbon atoms, including all isomeric forms, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentoxy, neopentoxy, sec-pentoxy, n-pentoxy, isopentoxy, tert-pentoxy and hexoxy.

25 The term " C_{3-7} cycloalkyl" refers to a cycloalkyl group consisting of from 3 to 7 carbon atoms, such as cyclopropane, cyclobutane, cyclopentane, cyclohexane and cycloheptane. Optional substituents for C_{3-7} cycloalkyl includes one or more halogen, hydroxy, oxo, C_{1-6} alkyl, cyano, CF_3 , OCF_3 , C_{1-6} alkoxy and C_{1-6} alkanoyl.

30 The term " C_{1-6} alkylthio" refers to a straight chain or branched chain alkylthio group having from one to six carbon atoms, such as methylthio, ethylthio, propylthio, isopropylthio, butylthio, isobutylthio, sec-butylthio, tert-butylthio, pentylthio, neopentylthio, sec-pentylthio, n-pentylthio, isopentylthio, tert-pentylthio and hexylthio.

35 The term "mono- or di- C_{1-6} alkylamino" refers to an amino group which is substituted by one C_{1-6} alkyl group or an amino group which is substituted by two C_{1-6} alkyl groups, the two amino groups being the same or different. Examples of mono- C_{1-6} alkylamino include methylamine, ethylamine, propylamine, isopropylamine, butylamine, isobutylamine, sec-butylamine, tert-butylamine, pentylamine, neopentylamine, sec-pentylamine, n-pentylamine, isopentylamine, tert-pentylamine and hexylamine. Examples of di- C_{1-6} alkylamino include dimethylamine, diethylamine, dipropylamine, diisopropylamine, dibutylamine, diisobutylamine, disec-butylamine, ditert-butylamine, dipentylamine,

40

dineopentylamine, dihexylamine, butylmethylamino, isopropylmethylamino, ethylisopropylamino, ethylmethylamino, etc.

5 The term "aryl" is used herein to describe groups such as phenyl or naphthyl, which may be optionally substituted by one or more of C₁₋₆alkyl (to form "arylC₁₋₆alkyl"), halogen, CF₃ or C₁₋₆alkoxy (to form "arylC₁₋₆alkoxy").

10 The terms "halo C₁₋₆alkoxy" or "haloC₁₋₆alkyl" are used to describe a C₁₋₆alkoxy or a C₁₋₆alkyl group, respectively, substituted with one or more halogens. Examples include -CHCl₂, -CF₃, -OCF₃, etc.

15 The term "heterocyclic group" is used herein to describe a stable aromatic or non-aromatic ring containing 1, 2 or 3 heteroatoms selected from nitrogen, sulphur and oxygen. Suitable examples of 4 to 7 membered heterocyclic groups include azetidiny, pyrrolidiny, imidazolidiny, pyrazolidiny, oxazolinyl, isothiazolidiny, thiazolidiny, pyrrolyl, pyrrolinyl, pyrazolinyl, imidazolyl, pyrazolyl, isothiazolyl, thiazolyl, piperidyl, piperazinyl, morpholinyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, azepinyl, azepanyl, dioxolanyl, thienyl, tetrahydrothienyl, tetrahydrofuryl, dioxanyl and dithianyl.

20 The term "N-linked heterocyclic group" is used herein to describe a heterocyclic group which is linked to the remainder of the molecule via a nitrogen atom. Suitable examples of 4 to 7 membered N-linked heterocyclic groups include azetidiny, pyrrolidiny, imidazolidiny, pyrazolidiny, oxazolinyl, isothiazolidiny, thiazolidiny, pyrrolyl, pyrrolinyl, pyrazolinyl, imidazolyl, pyrazolyl, piperidyl, piperazinyl, morpholinyl and azepanyl.

25 The term "C-linked heterocyclic group" is used herein to describe a heterocyclic group which is linked to the remainder of the molecule via a carbon atom. Suitable examples of 4 to 7 membered C-linked heterocyclic groups include azetidiny, pyrrolidiny, imidazolidiny, pyrazolidiny, oxazolinyl, isothiazolidiny, thiazolidiny, pyrrolyl, pyrrolinyl, 30 pyrazolinyl, imidazolyl, pyrazolyl, isothiazolyl, thiazolyl, piperidyl, piperazinyl, morpholinyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, azepinyl, azepanyl, dioxolanyl, thienyl, tetrahydrothienyl, tetrahydrofuryl, dioxanyl and dithianyl.

35 More than one optional substituent may be present in the N-linked or C-linked heterocycle, which may be the same or different, and may be attached to any carbon atom of the heterocycle or an available nitrogen atom.

40 Suitable optional substituents for the N-linked or C-linked heterocycle include C₁₋₆alkyl, amino, mono- or di- C₁₋₆alkylamino, aryl, arylC₁₋₆alkyl, arylamino, hydroxy, C₁₋₆alkylamido, hydroxyC₁₋₆alkyl, C₁₋₆alkoxycarbonyl, halogen, haloC₁₋₆alkyl, a heteroaromatic group (such as indole or benzimidazole), an aromatic or non-aromatic N-linked or C-linked heterocycle or an aromatic or non-aromatic heterocycleC₁₋₆alkyl optionally substituted by C₁₋₆alkyl. Examples of aromatic or non-aromatic heterocycleC₁₋

alkyl include heterocycle-methyl (such as pyridinyl-methyl and benzimidazolyl-methyl) and heterocycle-ethyl (such as morpholinyl-ethyl and indolyl-ethyl).

5 Substituents in the N-linked or C-linked heterocycle may form a bridge structure, to form a group such as for example 2-oxa-5-azabicyclo[2.2.1]heptyl. Such a bicyclic group may be further substituted by the substituents listed above. More than one substituent may be present on the same carbon atom to form spiro structures such as 1,4 and 1,5 dioxo spiro compounds.

10 When X is a group $-(CHR_5)-$, preferably R_5 is hydrogen. Preferably X is $-CH_2-$.

When \equiv is a single bond, preferably R_1 is hydrogen, hydroxy or C_{1-6} alkoxy.

Preferably R_2 is hydrogen.

15 When p is 2 or 3, R_3 may be the same or different. Preferably p is 1 or 2 and R_3 is/are halogen, particularly chloro or fluoro, attached at the 3 or the 3,4-positions of the phenyl ring.


20 Preferably R_4 is C_{1-6} alkoxy (particularly methoxy), OCF_3 , halogen or cyano.

Preferably Y is oxygen.

Preferably D is $-CH_2-$.

25 Preferably Z is an optionally substituted N-linked 4 to 7 membered heterocycle, in particular piperidyl. Preferred substituents include halogen (particularly fluoro) and C_{1-6} alkyl (particularly methyl).

30 Preferred compounds are compounds of formula (Ia):



wherein R_3 , p, R_4 , Y, D, Z, \equiv are as defined for formula (I) and X_1 is $-CH_2-$ or $-HC(OH)-$. Preferred features of formula (I) also apply to formula (Ia).

35 Preferred compounds include:

1. 1-(3,4-Dichloro-phenyl)-5-hydroxy-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-pyrrolidin-2-one
2. 1-(3,4-Dichloro-phenyl)-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-1,5-dihydro-pyrrole-2-one
- 5 3. 1-(3,4-Dichloro-phenyl)-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-pyrrolidin-2-one
4. 1-(3,4-Dichloro-phenyl)-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-3-methyl-pyrrolidin-2-one
6. 1-(4-Methoxyphenyl)-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-1,5-dihydro-pyrrole-2-one
- 10 7. 1-(4-Methoxyphenyl)-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-pyrrolidin-2-one
8. 1-(3-Chloro-4-methoxy-phenyl)-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-pyrrolidin-2-one
- 15 9. 1-(3-Chloro-4-methoxy-phenyl)-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-1,5-dihydro-pyrrole-2-one
10. 1-(3-Fluoro-4-methoxy-phenyl)-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-pyrrolidin-2-one
11. 1-(3-Fluoro-4-methoxy-phenyl)-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-1,5-dihydro-pyrrole-2-one
- 20 12. 1-(3-Fluoro-phenyl)-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-pyrrolidin-2-one
13. 1-(3-Fluoro-phenyl)-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-1,5-dihydro-pyrrole-2-one
14. 1-(3,4-Dichloro-phenyl)-5,5-dimethyl-4-hydroxy-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-pyrrol-2-one
- 25 15. 1-(3,4-Dichloro-phenyl)-5,5-dimethyl-4-hydroxy-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-pyrrol-2-one

and pharmaceutically acceptable salts thereof.


The compounds of formula (I) can form acid addition salts. It will be appreciated that for use in medicine the salts of the compounds of formula (I) should be pharmaceutically acceptable. Suitable pharmaceutically acceptable salts will be apparent to those skilled in the art and include those described in J. Pharm. Sci., 1977, 66, 1-19, such as acid addition salts formed with inorganic acids e.g. hydrochloric, hydrobromic, sulfuric, nitric or phosphoric acid; and organic acids e.g. succinic, maleic, acetic, fumaric, citric, tartaric, benzoic, p-toluenesulfonic, methanesulfonic or naphthalenesulfonic acid.

The compounds of this invention may be in crystalline or non-crystalline form, and, if crystalline, may optionally be hydrated or solvated. This invention includes within its scope stoichiometric hydrates as well as compounds containing variable amounts of water.


Certain compounds of formula (I) are capable of existing in stereoisomeric forms (e.g. geometric or ("cis-trans") isomers, diastereomers and enantiomers) and the invention extends to each of these stereoisomeric forms and to mixtures thereof including racemates. The different stereoisomeric forms may be separated one from the other by the usual methods, or any given isomer may be obtained by stereospecific or asymmetric synthesis. The invention also extends to any tautomeric forms and mixtures thereof.

The present invention also provides a process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof, which process comprises:

(a) reacting a compound of formula (II):




wherein R_1 , R_2 , R_3 , R_4 , m , p , X , \equiv , Y and D are as defined for formula (I), and L is a leaving group, with a compound of formula (III):



wherein Z is as defined for formula (I); or

(b) cyclising a compound of formula (IV):



wherein R_1 , R_2 , m , R_3 , p , R_4 , Y , D , Z and \equiv are as defined for formula (I) and G is a group $-X=CH_2$, wherein X is as defined for formula (I), dehydrogenated as required;

and thereafter, for either process (a) or process (b), optionally followed by:

- removing any protecting groups; and/or
- converting a compound of formula (I) into another compound of formula (I); and/or
- forming a pharmaceutically acceptable salt.

5

For the reaction of process (a), suitably L is mesylate. The reaction may take place in a solvent such as DMF in the presence of sodium iodide and potassium carbonate.

10

The reaction of process (b) suitably takes place in a solvent such as THF in the presence of OsO₄ and NaIO₄.

15

Compounds of formula (I) can be converted into further compounds of formula (I) using standard techniques. For example, and by way of illustration rather than limitation, a compound wherein X is -(HCOH)- may be converted to a compound wherein X is -(CH₂)- by using a suitable reducing agent such as triethylsilane-trifluoroacetic acid using dichloromethane as solvent, and a compound wherein R₁ is hydroxy may be converted to compound wherein m is 0 and $\text{C}=\text{C}$ is a double bond by an elimination reaction in TFA.

20

Compounds of formulae (II), (III) and (IV) are commercially available or may be prepared according to methods described herein or may be prepared according to known methods or by analogous methods thereto.

25

Those skilled in the art will appreciate that it may be necessary to protect certain groups to carry out the above processes. Suitable protecting groups and methods for their attachment and removal are conventional in the art of organic chemistry, such as those described in Greene T.W. 'Protective groups in organic synthesis' New York, Wiley (1981).

30

Pharmaceutically acceptable salts may be prepared conventionally by reaction with the appropriate acid or acid derivative.

35

In another aspect, the present invention provides a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

40

In a further aspect, the present invention provides a process for preparing a pharmaceutical composition, the process comprising mixing a compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.

A pharmaceutical composition of the invention, which may be prepared by admixture, suitably at ambient temperature and atmospheric pressure, is usually adapted for oral, parenteral or rectal administration and, as such, may be in the form of tablets, capsules,

oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable or infusible solutions or suspensions or suppositories. Orally administrable compositions are generally preferred.

- 5 Tablets and capsules for oral administration may be in unit dose form, and may contain conventional excipients, such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose);, fillers (e.g. lactose, microcrystalline cellulose or calcium hydrogen phosphate);, tableting lubricants (e.g. magnesium stearate, talc or silica);, disintegrants (e.g. potato starch or sodium starch glycollate); and acceptable wetting agents (e.g. sodium lauryl sulphate). The tablets may be coated according to methods well known in normal pharmaceutical practice.

- 15 Oral liquid preparations may be in the form of, for example, aqueous or oily suspension, solutions, emulsions, syrups or elixirs, or may be in the form of a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents (e.g. sorbitol syrup, cellulose derivatives or hydrogenated edible fats), emulsifying agents (e.g. lecithin or acacia), non-aqueous vehicles (which may include edible oils e.g. almond oil, oily esters, ethyl alcohol or fractionated vegetable oils), preservatives (e.g. methyl or propyl-p-hydroxybenzoates or sorbic acid), and, if desired, conventional flavourings or colorants, buffer salts and sweetening agents as appropriate. Preparations for oral administration may be suitably formulated to give controlled release of the active compound.

- 25 For parenteral administration, fluid unit dosage forms are prepared utilising a compound of the invention or pharmaceutically acceptable salt thereof and a sterile vehicle. Formulations for injection may be presented in unit dosage form e.g. in ampoules or in multi-dose, utilising a compound of the invention or pharmaceutically acceptable salt thereof and a sterile vehicle, optionally with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use. The compound, depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions, the compound can be dissolved for injection and filter sterilised before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering agents are dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilisation cannot be accomplished by filtration. The compound can be sterilised by exposure to ethylene oxide before suspension in a sterile vehicle. Advantageously, a

surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.

5 Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilising agents, dispersing agents, suspending agents, thickening agents, or colouring agents. Drops may be formulated with an aqueous or non-aqueous base also comprising one or more dispersing agents, stabilising agents, solubilising agents or suspending agents. They may also contain a preservative.

10 The compounds of the invention may also be formulated in rectal compositions such as suppositories or retention enemas, e.g. containing conventional suppository bases such as cocoa butter or other glycerides.

15 The compounds of the invention may also be formulated as depot preparations. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds of the invention may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

20 For intranasal administration, the compounds of the invention may be formulated as solutions for administration via a suitable metered or unitary dose device or alternatively as a powder mix with a suitable carrier for administration using a suitable delivery device. Thus compounds of formula (I) may be formulated for oral, buccal, parenteral, topical
25 (including ophthalmic and nasal), depot or rectal administration or in a form suitable for administration by inhalation or insufflation (either through the mouth or nose).

30 The compounds of the invention may be formulated for topical administration in the form of ointments, creams, gels, lotions, pessaries, aerosols or drops (e.g. eye, ear or nose drops). Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents. Ointments for administration to the eye may be manufactured in a sterile manner using sterilised components.

35 The compounds of the present invention have affinity for the 5-HT_{2C} receptor. The affinity can be determined by assessing their ability to displace [³H]-mesulergine from rat or human 5-HT_{2C} clones expressed in 293 cells *in vitro*, as described in WO 94/04533.

40 All the Example compounds were tested according to this assay and were found to have pK_i values >5.8. Some compounds show a considerably higher affinity in the range of 7.0 to >9.0 in human cells.

The intrinsic activity of the compounds of this invention can be determined according to the [³⁵S]GTP_γS functional assay which is described in WO 99/07700.

5 Compounds of formula (I) and their pharmaceutically acceptable salts are of use in the treatment of certain CNS disorders such as depression (which term is used herein to include bipolar depression, unipolar depression, single or recurrent major depressive episodes with or without psychotic features, catatonic features, melancholic features, atypical features or postpartum onset, seasonal affective disorder, dysthymic disorders with early or late onset and with or without atypical features, neurotic depression and
10 social phobia, depression accompanying dementia for example of the Alzheimer's type, vascular dementia with depressed mood, schizoaffective disorder or the depressed type, and depressive disorders resulting from general medical conditions including, but not limited to, myocardial infarction, diabetes, miscarriage or abortion, *etc*), anxiety including generalised anxiety and social anxiety disorder, schizophrenia, panic disorder, agoraphobia, social phobia, epilepsy, obsessive compulsive disorder and post-traumatic stress disorder, pain (particularly neuropathic pain), migraine, memory disorders, including dementia, amnesic disorders and age-associated memory impairment, disorders of eating behaviours including anorexia nervosa and bulimia nervosa, sexual dysfunction, sleep disorders (including disturbances of circadian rhythm, dyssomnia, insomnia, sleep
20 apnea and narcolepsy), withdrawal from abuse of drugs such as of cocaine, ethanol, nicotine, benzodiazepines, alcohol, caffeine, phencyclidine (phencyclidine-like compounds), opiates (e.g. cannabis, heroin, morphine), sedative ipnotic, amphetamine or amphetamine-related drugs (e.g. dextroamphetamine, methylamphetamine) or a combination thereof, Alzheimer's disease, motor disorders such as Parkinson's disease, dementia in Parkinson's disease, neuroleptic-induced Parkinsonism and tardive dyskinesias, as well as other psychiatric disorders, disorders associated with spinal trauma and/or head injury such as hydrocephalus, gastrointestinal disorders such as IBS (Irritable Bowel Syndrome), Crohn's disease, ulcerative colitis, non-steroidal anti-inflammatory drug induced damage) as well as microvascular diseases such as macular
25 oedema and retinopathy.
30

It is to be understood that, as used herein, the term "treatment" refers to alleviation of established symptoms as well as prophylaxis.

35 Thus the present invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, for use as a therapeutic substance. In particular, the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment of the above disorders. In particular the invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for use
40 as a therapeutic substance in the treatment of a CNS disorder. Preferably the CNS disorder is depression or anxiety.

Compounds of the invention may be administered in combination with other active substances such as 5HT3 antagonists, NK-1 antagonists, serotonin agonists, selective serotonin reuptake inhibitors (SSRI), noradrenaline re-uptake inhibitors (SNRI), tricyclic antidepressants and/or dopaminergic antidepressants.

5

Suitable 5HT3 antagonists which may be used in combination of the compounds of the inventions include for example ondansetron, granisetron, metoclopramide.

10

Suitable serotonin agonists which may be used in combination with the compounds of the invention include sumatriptan, rauwolscine, yohimbine, metoclopramide.

15

Suitable SSRIs which may be used in combination with the compounds of the invention include fluoxetine, citalopram, femoxetine, fluvoxamine, paroxetine, indalpine, sertraline, zimeldine.

Suitable SNRIs which may be used in combination with the compounds of the invention include venlafaxine and reboxetine.

20

Suitable tricyclic antidepressants which may be used in combination with a compound of the invention include imipramine, amitriptyline, chlomipramine and nortriptyline.

Suitable dopaminergic antidepressants which may be used in combination with a compound of the invention include bupropion and amineptine.

25

It will be appreciated that the compounds of the combination or composition may be administered simultaneously (either in the same or different pharmaceutical formulations), separately or sequentially.

30

The invention further provides a method of treatment of the above disorders in mammals including humans, which comprises administering to the sufferer a therapeutically safe and effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. In particular the invention provides a method of treatment of a CNS disorder in mammals including humans, which comprises administering to the sufferer a therapeutically safe and effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. Preferably the disorder is depression or anxiety.

35

40


In another aspect, the invention provides for the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the treatment of the above disorders. In particular the present invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the treatment of a CNS disorder. Preferably the CNS disorder is depression or anxiety.

The composition of the present invention may contain from 0.1% to 99% by weight, preferably from 10 to 60% by weight, of the active material, depending on the method of administration. The dose of the compound used in the treatment of the aforementioned disorders will vary in the usual way with the seriousness of the disorders, the weight of the sufferer, and other similar factors. However, as a general guide suitable unit doses may be 0.05 to 1000 mg, more suitably 1.0 to 200 mg, and such unit doses may be administered more than once a day, for example two or three times a day. Such therapy may extend for a number of weeks or months. When administered in accordance with the invention, no unacceptable toxicological effects are expected with the compounds of the invention.

All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

The following Descriptions and Examples illustrate the preparation of compounds of the present invention.


Preparation 1: [4-Methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-acetic acid 2-piperidin-1-yl-ethyl ester



A mixture of (3-hydroxy-4-methoxy-phenyl)-acetic acid (1.85 g), dry DMF (25 ml), K_2CO_3 (5.9 g) and *N*-chloroethylpiperidine hydrochloride (3.74 g) was heated at 40 °C for 5 h. Volatiles were then removed *in vacuo* and the residue partitioned between water and EtOAc. The organic layer was washed (brine) and concentrated to give the title (3.76 g) compound as an orange oil.

NMR (1H , $CDCl_3$): δ 6.93-6.80 (m, 3H), 4.22 (t, 2H), 4.14 (t, 2H), 3.82 (s, 3H), 3.55 (s, 2H), 2.82 (t, 2H), 2.66-2.40 (m, 10H), 1.66-1.40 (m, 12H).

Preparation 2: [4-Methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-acetic acid methyl ester




[4-Methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-acetic acid 2-piperidin-1-yl-ethyl ester (6.3 g) in MeOH (6 ml), THF (6 ml) and water (6 ml) containing KOH (1.7 g) was heated at 45 °C for 1 h and then allowed to cool to 25 °C over 90 min. With stirring in an ice bath conc. aqueous HCl (6 ml) was then added. The mixture was evaporated to dryness. The

material was heated at reflux with HCl in MeOH (1 M) for 4 h, concentrated and extracted with CH₂Cl₂. The mixture was filtered and the solvent removed *in vacuo* to give the title compound (4.4 g) as an orange oil.

NMR (¹H, CDCl₃): δ 6.88-6.79 (m, 3H), 4.18 (t, 2H), 3.84 (s, 3H), 3.69 (s, 3H), 3.55 (s, 2H), 2.87 (t, 2H), 2.56 (bs, 4H), 1.66 (bs, 4H), 1.46 (bs, 2H).


Preparation 3: 2-[4-Methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-pent-4-enoic acid methyl ester



Procedure: To a solution of [4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-acetic acid methyl ester (2.1 g) in THF (dry, 15 ml) at -78 °C was slowly added lithium bis(trimethylsilyl)amide (1 M in THF, 8.2 ml). The solution was stirred at this temperature for 15 min before allyl bromide (0.59 ml) was added. After additional 30 min water and EtOAc were added with stirring. The mixture was allowed to warm to 25 °C, layers separated and the organic layer washed (brine), concentrated and submitted to column chromatography (silica gel, CH₂Cl₂ / MeOH / NH₃) to give the title compound (1.3 g) as a colourless oil.

NMR (¹H, CDCl₃): δ 6.90-6.80 (m, 3H), 5.76-5.67 (m, 1H), 5.10-4.98 (m, 2H), 4.18 (bs, 2H), 3.83 (s, 3H), 3.65 (s, 3H), 3.56 (t, 1H), 2.86 (bs, 2H), 2.83-2.73 (m, 1H), 2.65-2.45 (m, 5H), 1.65 (bs, 4H), 1.47 (bs, 2H). **MS (m/z):** 348 [MH]⁺.


Preparation 4: 2-[4-Methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-pent-4-enoic acid hydrochloride salt



2-[4-Methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-pent-4-enoic acid methyl ester (1.3 g) in MeOH (2 ml), THF (2 ml) and water (2 ml) containing KOH (0.42 g) was heated at 45 °C for 1 h and then allowed to cool to 25 °C. The mixture was evaporated to dryness. THF (5 ml) and conc. aqueous HCl (0.62 ml) were added, the mixture concentrated, extracted with CH₂Cl₂, filtered and the solvent removed *in vacuo* to give the title compound (1.2 g) as an off-white foam.

NMR (¹H, CD₃OD): δ 7.05 (d, 1H), 6.96 (dd, 1H), 6.91 (d, 1H), 5.81-5.70 (m, 1H), 5.02 (dd, 1H), 4.92 (dd, 1H), 4.31 (dd, 2H), 3.83 (s, 3H), 3.48-3.42 (m, 3H), 3.37-3.28 (m, 4H), 2.78-2.69 (m, 1H), 2.44-2.35 (m, 1H), 1.91-1.84 (m, 4H), 1.72-1.63 (m, 2H). **MS (m/z):** 334 [MH]⁺.


Preparation 5: 2-[4-Methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-pent-4-enoic acid (3,4-dichlorophenyl)-amide



To a solution of 2-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-pent-4-enoic acid hydrochloride salt (0.46 g) in dry CH_2Cl_2 (4 ml), under N_2 , was added, at 0°C , oxalyl chloride (0.11 ml) and DMF (cat). After 30 min the reaction mixture was concentrated to dryness *in vacuo*. To this material was added toluene (dry, 4 ml) and 3,4-dichloroaniline (0.20 g). The mixture was heated at 105°C for 4 h, then partitioned between aqueous NaHCO_3 and EtOAc. The organic layer was washed (brine), concentrated and purified by column chromatography (silica gel, CH_2Cl_2 / MeOH / NH_3) to give the title compound (0.35 g) as a slightly brown oil.

NMR (^1H , CDCl_3): δ 7.74 (s, 1H), 7.55 (bs, 1H), 7.31 (bs, 2H), 6.96 (bs, 1H), 6.91-6.83 (m, 2H), 5.77-5.68 (m, 1H), 5.09 (d, 1H), 5.01 (d, 1H), 4.23-4.16 (m, 2H), 3.85 (s, 3H), 3.53 (t, 1H), 2.99-2.91 (m, 1H), 2.83 (t, 2H), 2.55 (bs, 4H), 1.68-1.62 (m, 4H), 1.47 (bs, 3H). **MS (m/z):** 477 $[\text{MH}]^+$, 2Cl.


Preparation 6: 2-[4-Methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-propanoic acid methyl ester



To a solution of [4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-acetic acid methyl ester (0.60 g) in THF (dry, 6 ml) at -78°C was slowly added lithium bis(trimethylsilyl)amide (1 M in THF, 2.3 ml). The solution was stirred at this temperature for 15 min before iodomethane (0.12 ml) was added, then allowed to warm to 25°C . After 16 h aqueous NaHCO_3 and EtOAc were added with stirring, layers separated and the organic layer washed (brine), concentrated and submitted to column chromatography (silica gel, CH_2Cl_2 / MeOH / NH_3) to give the title compound (0.27 g) as a slightly yellow oil.

NMR (^1H , CD_3OD): δ 6.88-6.75 (m, 3H), 4.12 (t, 2H), 3.80 (s, 3H), 3.67-3.34 (m, 4H), 2.78 (t, 2H), 2.50 (bs, 4H), 1.65-1.37 (m, 9H). **MS (m/z):** 322 $[\text{MH}]^+$.

Preparation 7: 2-(3,4-Dichloro-phenylamino)-2-methyl-propionic acid




To a solution of 3,4-dichloroaniline (2 g, 12.4 mmol) and 1,1,1-trichloro-2-methyl-2-propanol 0.5 hydrate (3.47 g, 18.63 mmol) in acetone (25 ml) was added KOH (2.79 g,

49.7 mmol) at 0 °C, and the mixture was stirred for 1 h at 0 °C and overnight at room temperature. The reaction mixture was concentrated *in vacuo*, diluted with water, and washed with diethyl ether. The aqueous solution was acidified with citric acid and extracted with AcOEt (3x150 ml). The organic layer was washed with brine, dried over anhydrous NaSO₄ and concentrated *in vacuo* to give the title compound in 2.2 g yield as a white solid (72%).

NMR (¹H, DMSO): δ 12.30 (bs, 1H), 7.18 (d, 1H), 6.60 (s, 1H), 6.40 (dd, 1H), 4.98 (bs, 1H), 1.40 (s, 4H).


10 Preparation 8: Methyl 2-(3,4-dichloro-phenylamino)-2-methyl-propionate



To a solution of 2-methyl-2-(3,4-dichloroaniline)-propionic acid (0.50 g, 2.02 mmol) in MeOH+CH₂Cl₂ (14+7 ml) were added triethylamine (0.57 ml, 4.08 mmol) and Me₃SiCHN₂ (2M in hexane, 6.06 mmol) at 0 °C. The reaction mixture was stirred for 4 h at room temperature, concentrated *in vacuo* and the crude product purified by flash chromatography (AcOEt:cyclohexane=1:9) to give the title compound in 489 mg yield as white solid (93%).


NMR (¹H, DMSO): δ 7.42 (dd, 1H), 6.57 (d, 1H), 6.46 (s, 1H), 6.35 (dd, 1H), 3.62 (s, 3H), 1.45 (s, 6H).

Preparation 9: 2-[4-Methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-acetic acid hydrochloride salt




To a solution of methyl-2-(3-[2-piperidin-1-yl-ethoxy]-4-methoxy-phenyl)-acetate (0.59 g, 1.92 mmol) in THF+MeOH (1+1 ml) at 25 °C was added a solution of KOH (0.21 g, 3.84 mmol) in H₂O (1 ml). The solution was heated at 45 °C for 1.5 hours. After removing the solvent *in vacuo* the residue was dissolved in THF and acidified at 0 °C with conc. aqueous HCl. The mixture was concentrated to dryness *in vacuo*, the crude was extracted with PrOH/CH₂Cl₂ (1/1), filtered and concentrated to dryness *in vacuo* to give the title compound in 544 mg yield as brown solid (y= 96%). **MS (m/z):** 294 [MH]⁺.

35 Preparation 10: 2-((3,4-Dichloro-phenyl)-{2-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-acetyl}-amino)-2-methyl propionic acid methyl ester



To a solution of 2-(3-[2-piperidin-1-yl-ethoxy]-4-methoxy-phenyl)-acetic acid hydrochloride salt (0.62 g, 1.89 mmol) in CH₂Cl₂ (9 ml) at 0 °C were added oxalyl chloride (0.33 ml, 3.78 mmol) and DMF (some drops). The solution was stirred at room temperature for 1.5 hours and concentrated to dryness *in vacuo*. The crude was dissolved in 1,4-dioxane, added with a solution of methyl-2-methyl-2-(3,4-dichloroaniline)-propionate (0.47 g, 1.78 mmol) in 1,4-dioxane and heated at 90 °C for 20 hours. The reaction mixture was concentrated *in vacuo*, dissolved in CH₂Cl₂, washed with conc. aqueous NaHCO₃, brine and dried over anhydrous NaSO₄. After purification by flash chromatography (CH₂Cl₂:MeOH=9:1) the title compound was obtained in 681 mg yield as a brown oil (61%). **MS (m/z):** 537 [MH]⁺ (2Cl).


Example 1: 1-(3,4-Dichloro-phenyl)-5-hydroxy-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-pyrrolidin-2-one



To a solution of 2-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-pent-4-enoic acid (3,4-dichlorophenyl)-amide (0.30 g) in THF/H₂O (5/1, 12 ml) was added OsO₄ (4% wt in water, 0.2 ml) and NaIO₄ (0.41 g). After 20 hours excess aqueous Na₂S₂O₃ was added with stirring. After 5 min. the mixture was partitioned between sat. aqueous NaHCO₃ and EtOAc. The organic layer was washed (brine), concentrated to dryness *in vacuo* and the residue purified by column chromatography to give the title product as a colourless foam (0.20 g, ca. 2:1 mixture of diastereoisomers):

NMR (¹H, CDCl₃): δ 7.80 and 7.74 (2d, 1H), 7.55-7.35 (m, 2H), 7.00 (s, 0.33H), 6.92 (d, 0.33H), 6.83-6.70 (m, 2.34H), 5.70-5.59 (m, 1H), 4.17-4.00 (m, 3.67H), 3.82 (s, 3H), 3.70 (dd, 0.33H), 2.95-2.85 (m, 0.33H), 2.77 (t, 2H), 2.55-2.34 (m, 5.34H), 2.17-2.08 (m, 0.33H), 1.62-1.50 (m, 4H), 1.46-1.35 (m, 2H). **MS (m/z):** 479 [MH]⁺, 2Cl.

Example 2: 1-(3,4-Dichloro-phenyl)-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-1,5-dihydro-pyrrole-2-one




To 1-(3,4-dichloro-phenyl)-5-hydroxy-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-pyrrolidin-2-one (0.13 g) in CH₂Cl₂ (dry, 5 ml) and Et₃SiH (0.13 ml) at 0 °C was added

dropwise a solution of trifluoroacetic acid (0.22 ml) in CH₂Cl₂ (dry, 1 ml). The mixture was allowed to warm to 25 °C. After 20 h volatiles were removed *in vacuo* and the residue submitted to column chromatography (silica gel, CH₂Cl₂ / MeOH / NH₃) to give a mixture of 1-(3,4-dichloro-phenyl)-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-pyrrolidin-2-one and 1-(3,4-dichloro-phenyl)-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-1,5-dihydro-pyrrole-2-one. On trituration with EtOAc : petroleum ether (40-60) 1:2 the title compound was obtained as an off-white solid.

NMR (¹H, CDCl₃): δ 7.99 (d, 1H), 7.70 (dd, 1H), 7.54-7.50 (m, 2H), 7.46 (d, 1H), 7.22 (t, 1H), 6.92 (d, 1H), 4.43 (d, 2H), 4.23 (t, 2H), 3.91 (s, 3H), 2.87 (t, 2H), 2.56 (bs, 4H), 1.70-1.60 (m, 4H), 1.47 (bs, 2H). **MS (m/z):** 461 [MH]⁺, 2Cl. **mp :** 98-99 °C.


Example 3: 1-(3,4-Dichloro-phenyl)-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-pyrrolidin-2-one



The title compound (22 mg) was obtained as a colourless film from the mother liquor from Example 2 by removal of the volatiles, extraction with hexane and concentration of the hexane solubles *in vacuo*.

NMR (¹H, CDCl₃): δ 7.87 (d, 1H), 7.60 (dd, 1H), 7.43 (d, 1H), 6.89-6.83 (m, 3H), 4.17 (t, 2H), 3.95-3.80 (m, 6H), 2.82 (t, 2H), 2.70-2.60 (m, 1H), 2.52 (bs, 4H), 2.35-2.25 (m, 1H), 1.64-1.58 (m, 4H), 1.50-1.42 (m, 2H). **MS (m/z):** 463 [MH]⁺, 2Cl.

Example 4: 1-(3,4-Dichloro-phenyl)-5-methoxy-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-pyrrolidin-2-one




1-(3,4-Dichloro-phenyl)-5-hydroxy-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-pyrrolidin-2-one was treated with MeOH (dry, 2 ml) containing pyridinium 4-toluenesulfonate (42 mg) at 25 °C for 4 days, at 50 °C for 4 h and at 60 °C for 6 h. The mixture was partitioned between aqueous NaHCO₃ and EtOAc. The organic layer was collected, concentrated and submitted to column chromatography (silica gel, CH₂Cl₂ / MeOH / NH₃). A major diastereoisomer (3,5-*trans* substitution of the pyrrolidin-2-one, 25 mg slightly yellow film) was isolated besides a *ca.* 1:1 mixture of the major and the minor diastereoisomer (4 mg colourless film) and recovered unreacted starting material (21 mg 1-(3,4-dichloro-phenyl)-5-hydroxy-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-pyrrolidin-2-one).

Major diastereoisomer: NMR (¹H, CDCl₃): δ 7.81 (d, 1H), 7.51 (d, 1H), 7.45 (d, 1H), 6.90-6.82 (m, 3H), 5.32 (d, 1H), 4.17 (t, 2H), 4.02 (dd, 1H), 3.85 (s, 3H), 3.41 (s, 3H), 2.84

(t, 2H), 2.64 (dd, 1H), 2.56 (bs, 4H), 2.37-2.30 (m, 1H), 1.67-1.60 (m, 4H), 1.50-1.40 (m, 2H). **MS (m/z):** 493 [MH]⁺, 2Cl.

Ca. 1:1 mixture of major and minor diastereoisomer: NMR (¹H, CDCl₃): δ 7.82 and 7.74 (2d, 1H), 7.51 (d, 0.5H), 7.48-7.42 (m, 1H), 7.03 (d, 0.5H), 6.97 (dd, 0.5 H), 6.91-6.83 (m, 2.5H), 5.37-5.33 (m, 1H), 4.26-4.20 (m, 2H), 4.02 (dd, 0.5H), 3.85 (2s, 3H), 3.77 (dd, 0.5H), 3.41 and 3.38 (2s, 3H), 2.89 (bs, 2H), 2.85-2.78 (m, 0.5H), 2.70-2.50 (m, 4.5H), 2.37-2.24 (m, 1H), 1.66 (bs, 4H), 1.48 (bs, 2H). **MS (m/z):** 493 [MH]⁺, 2Cl.

Example 5: 1-(3,4-Dichloro-phenyl)-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-3-methyl-pyrrolidin-2-one



To a solution of 2-[4-Methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-propanoic acid methyl ester (0.27 g) in THF (dry, 5 ml) at -78 °C was slowly added lithium bis(trimethylsilyl)amide (1 M in THF, 1.0 ml). The solution was stirred at this temperature for 15 min before allyl bromide (0.11 ml) was added. The mixture was allowed to warm to 0 °C and kept at that temperature for 1.5 h. It was then partitioned between aqueous NaHCO₃ and EtOAc, layers separated and the organic layer washed (brine), concentrated and submitted to column chromatography (silica gel, CH₂Cl₂ / MeOH / NH₃) to give a colourless oil (0.14 g).

This material in MeOH (1 ml) containing KOH (5 eq.) was heated at 45 °C for 3 h and then and then kept at 25 °C for 18 h. The mixture was evaporated to dryness. Excess aqueous HCl was added, the mixture concentrated, extracted with CH₂Cl₂, filtered and the solvent removed *in vacuo* to give a colourless foam (0.09 g).

To this material in dry CH₂Cl₂ (1 ml), under N₂, was added, at 0 °C, oxalyl chloride (0.03 ml) and DMF (cat). After 1 h the reaction mixture was concentrated to dryness *in vacuo*. To this material was added dioxane (dry, 1 ml) and 3,4-dichloroaniline (0.04 g). The mixture was heated at 95 °C for 4 h, concentrated *in vacuo* and purified by column chromatography (silica gel, CH₂Cl₂ / MeOH / NH₃) to give an orange oil (0.06 g).


This material was converted to 1-(3,4-dichloro-phenyl)-5-hydroxy-3-methyl-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-pyrrolidin-2-one (37 mg colourless film) in analogy to the procedure described for Example 1.

To 1-(3,4-dichloro-phenyl)-5-hydroxy-3-methyl-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-pyrrolidin-2-one (30 mg) in CH₂Cl₂ (dry, 0.5 ml) and Et₃SiH (0.049 ml) was added dropwise a solution of trifluoroacetic acid (0.047 ml) in CH₂Cl₂ (dry, 0.5 ml) at 0 °C. The mixture was allowed to warm to 25 °C. After 7.5 h volatiles were removed *in vacuo* and the residue submitted to column chromatography (silica gel, CH₂Cl₂ / MeOH / NH₃) to give the title compound (19 mg) as a colourless film.

NMR (¹H, CDCl₃): δ 7.88 (d, 1H), 7.57 (dd, 1H), 7.41 (d, 1H), 7.01 (d, 1H), 6.92 (dd, 1H), 6.82 (d, 1H), 4.14 (t, 2H), 3.84 (s, 3H), 3.75-3.66 (m, 2H), 2.79 (t, 2H), 2.64-2.57 (m, 1H),

2.58 (bs, 4H), 2.29-2.21 (m, 1H), 1.65-1.55 (m, 7H), 1.50-1.40 (m, 2H). **MS (m/z):** 477 [MH]⁺, 2Cl.

Example 6: 1-(4-Methoxyphenyl)-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-1,5-dihydro-pyrrole-2-one hydrochloride




To a solution of 2-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-pent-4-enoic acid (4-methoxyphenyl)-amide (prepared in an analogous way to Procedure 5, 570 mg, 1.3 mmol) in acetone/H₂O 8/1 (33 ml) was added N-methyl-morpholine-N-oxide (2eq, 304 mg) and OsO₄ (4wt% sol. in water, cat., 0.84 ml). The reaction was stirred at room temperature for 6 hours and then quenched with 40 ml of Na₂SO₃ sat. After 15 minutes stirring the diol was extracted with ethyl acetate (2x20 ml), dried over Na₂SO₄, filtered and concentrated to dryness *in vacuo*.

The crude product was then dissolved in THF/H₂O 1/1 (30 ml) and potassium periodate (1.5 eq, 391 mg) was added. The reaction mixture was stirred at room temperature for 3 hours. The solution was diluted with water (20 ml) and extracted with ethyl acetate (3x20 ml). The combined organic extracts were dried over anhydrous Na₂SO₄, filtered and concentrated to dryness *in vacuo*. Flash chromatography of the crude product (silica gel, CH₂Cl₂/MeOH/NH₃ aq. 150/10/1) gave 245 mg of the cyclized product.

This material (130 mg) was dissolved in TFA (2.5 ml). The reaction mixture was stirred at room temperature for 2 hours, then concentrated *in vacuo*. A saturated solution of NaHCO₃ was added and the mixture was extracted with ethyl acetate, dried over Na₂SO₄ and concentrated *in vacuo*. The residue was dissolved in CH₂Cl₂ and HCl (1M in Et₂O, 2 ml) was added, the volatiles evaporated and the residue triturated with Et₂O to give 130 mg of the title product as a light pink solid:

NMR (¹H, DMSO-d₆): δ 9.9 (bs 1H), 7.71 (d, 2H), 7.7-6.64 (m, 2H), 7.67 (t, 1H), 7.09 (d, 1H), 6.99 (d, 2H), 4.56 (d, 2H), 4.39 (bt, 2H), 3.81 (s, 3H), 3.76 (s, 3H), 3.58 (m, 2H), 3.50 (m, 2H), 3.04 (m, 2H), 1.81 (m, 4H), 1.7 (m, 1H), 1.4 (m, 1H). **MS (m/z):** 423 [MH]⁺.


Example 7: 1-(4-Methoxyphenyl)-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-pyrrolidin-2-one hydrochloride



The product was prepared in an analogous way to the one described for Example 3.


NMR (^1H , DMSO- d_6): δ 9.87 (bs, 1H), 7.58 (d, 2H), 7.0-6.8 (m, 5H), 4.33 (t, 2H), 3.85 (m, 2H), 3.84 (t, 1H), 3.77 (s, 3H), 3.74 (s, 3H), 3.55 (d, 2H), 3.45 (m, 2H), 3.02 (m, 2H), 2.53 (m, 1H), 2.16 (m, 1H), 1.85-1.65 (m, 5H), 1.39 (m, 1H). **MS (m/z):** 425 $[\text{MH}]^+$.

Example 8: 1-(3-Chloro-4-methoxy-phenyl)-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-pyrrolidin-2-one hydrochloride




The product was prepared in an analogous way to the one described for Example 3.
NMR (^1H , DMSO- d_6): δ 9.75 (bs, 1H), 7.89 (d, 1H), 7.53 (dd, 1H), 7.17 (d, 1H), 6.99 (m, 2H), 6.90 (dd, 1H), 4.32 (t, 2H), 3.87 (m, 3H), 3.83 (s, 3H), 3.81 (s, 3H), 3.55 (m, 2H), 3.45 (m, 2H), 3.0 (m, 2H), 2.5 (m, 1H), 2.15 (m, 1H), 1.9 (m, 4H), 1.4 (m, 2H). **MS (m/z):** 459 $[\text{MH}]^+$, 1Cl.

Example 9: 1-(3-Chloro-4-methoxy-phenyl)-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-1,5-dihydro-pyrrole-2-one hydrochloride



The product was prepared in an analogous way to the one described for Example 6.
NMR (^1H , DMSO- d_6): δ 9.76 (bs, 1H), 8.01 (d, 1H), 7.68 (m, 4H), 7.19 (d, 1H), 7.08 (d, 1H), 4.59 (d, 2H), 4.38 (t, 2H), 3.85 (s, 3H), 3.81 (s, 3H), 3.58 (m, 2H), 3.50 (m, 2H), 3.04 (m, 2H), 1.85 (m, 4H), 1.4 (m, 2H). **MS (m/z):** 457 $[\text{MH}]^+$, 1Cl.


Example 10: 1-(3-Fluoro-4-methoxy-phenyl)-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-pyrrolidin-2-one hydrochloride



The product was prepared in an analogous way to the one described for Example 3.
NMR (^1H , DMSO- d_6): δ 9.82 (bs, 1H), 7.74 (dd, 1H), 7.36 (dd, 1H), 7.17 (t, 1H), 6.99 (m, 2H), 6.90 (dd, 1H), 4.32 (t, 2H), 3.87 (m, 3H), 3.82 (s, 3H), 3.76 (s, 3H), 3.54 (m, 2H), 3.45

(m, 2H), 3.0 (m, 2H), 2.5 (m, 1H), 2.16 (m, 1H), 1.85 (m, 4H), 1.4 (m, 2H). **MS (m/z):** 443 [MH]⁺.


5 **Example 11: 1-(3-Fluoro-4-methoxy-phenyl)-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-1,5-dihydro-pyrrole-2-one hydrochloride**



The product was prepared in an analogous way to the one described for Example 6.

10 **NMR (¹H, DMSO-d₆):** δ 9.87 (bs, 1H), 7.84 (dd, 1H), 7.68 (m, 2H), 7.66 (dd, 1H), 7.51 (m, 1H), 7.21 (t, 1H), 7.08 (d, 1H), 4.58 (d, 2H), 4.39 (t, 2H), 3.84 (s, 3H), 3.81 (s, 3H), 3.57 (bd, 2H), 3.49 (m, 2H), 3.04 (m, 2H), 1.9-1.75 (m, 5H), 1.4 (m, 1H). **MS (m/z):** 441 [MH]⁺.


15 **Example 12: 1-(3-Fluoro-phenyl)-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-pyrrolidin-2-one hydrochloride**



The product was prepared in an analogous way to the one described for Example 3.

20 **NMR (¹H, DMSO-d₆):** δ 9.75 (bs, 1H), 7.70 (m, 1H), 7.47 (m, 1H), 7.43 (m, 1H), 7.0 (m, 1H), 7.0 (m, 2H), 6.92 (dd, 1H), 4.32 (t, 2H), 3.90 (m, 3H), 3.77 (s, 3H), 3.54 (m, 2H), 3.46 (m, 2H), 3.0 (m, 2H), 2.5-2.2 (m, 2H), 1.82 (m, 4H), 1.4 (m, 2H). **MS (m/z):** 413 [MH]⁺.


25 **Example 13: 1-(3-Fluoro-phenyl)-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-1,5-dihydro-pyrrole-2-one hydrochloride**



The product was prepared in an analogous way to the one described for Example 6.

30 **NMR (¹H, DMSO-d₆):** δ 9.9 (bs, 1H), 7.82 (m, 1H), 7.73 (t, 1H), 7.66 (m, 2H), 7.60 (dd, 1H), 7.45 (m, 1H), 7.09 (d, 1H), 6.97 (m, 1H), 4.62 (d, 2H), 4.39 (t, 2H), 3.82 (s, 3H), 3.57 (m, 2H), 3.48 (m, 2H), 3.02 (m, 2H), 1.9 (m, 4H), 1.4 (m, 2H). **MS (m/z):** 411 [MH]⁺.

Example 14: 1-(3,4-Dichloro-phenyl)-5,5-dimethyl-4-hydroxy-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-pyrrol-2-one




5

To a solution of 2-((3,4-dichloro-phenyl)-{2-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-acetyl}-amino)-2-methyl propionic acid methyl ester (0.19 g, 0.35 mmol) in CH_2Cl_2 +THF (1.5+1.5 ml) at 0 °C was added NaH (60% in mineral oil, 13.9 mg, 0.35 mmol). The solution was stirred at room temperature for 1.5 hours, cooled at 0 °C and HCl (1M in Et_2O , 0.35 mmol) was added. After stirring the solution at room temperature for 15 minutes, the solvent was removed *in vacuo*, the crude was dissolved in CH_2Cl_2 , filtered and concentrated to dryness *in vacuo*. After purification by flash chromatography CH_2Cl_2 :MeOH=(9:1) the title compound was obtained in 143 mg yield as a yellow solid (82%).

15 **NMR (^1H , DMSO):** δ 9.50 (bs, 1H), 8.16 (bs, 1H), 7.97 (bd, 1H), 7.83 (d, 1H), 7.53 (d, 1H), 7.34 (dd, 1H), 6.87 (d, 1H), 4.21 (t, 2H), 3.83 (t, 2H), 3.69 (s, 3H), 3.27 (m, 4H), 1.71 (m, 4H), 1.50 (bm, 2H), 1.25 (s, 6H). **MS (m/z):** 505 $[\text{MH}]^+$ (2Cl).

20 **Example 15: 1-(3,4-Dichloro-phenyl)-5,5-dimethyl-4-hydroxy-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-pyrrol-2-one hydrochloride salt**




25 To a solution of 1-(3,4-dichloro-phenyl)-5,5-dimethyl-4-hydroxy-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-pyrrol-2-one in CH_2Cl_2 was added excess HCl (1M in Et_2O). The resulting mixture was evaporated to dryness and the residue triturated with Et_2O and dried to give the title compound in 5 mg yield as a white solid (66%).

Claims

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof:

5 wherein:



R₁ is hydrogen, fluoro, chloro, hydroxy, C₁-6alkyl, C₃-7cycloalkyl, C₃-7cycloalkyloxy, C₁-6alkoxy or haloC₁-6alkoxy;

m is 0 when $\text{C}=\text{C}$ is a double bond and m is 1 when $\text{C}-\text{C}$ is a single bond;

10 R₂ is hydrogen, halogen, cyano, nitro, C₁-6alkyl, C₃-7cycloalkyl, C₃-7cycloalkyloxy, haloC₁-6alkyl, C₁-6alkoxy, haloC₁-6alkoxy, C₁-6alkylthio, amino, mono- or di-C₁-6alkylamino or an N-linked 4 to 7 membered heterocyclic group;

15 X is -(CH₂-CH₂)-, -(CH=CH)-, -(CH₂)₃-, -C(CH₃)₂-, -(CH=CH-CH₂)-, -(CH₂-CH=CH)- or a group -(CHR₅)- wherein R₅ is hydrogen, halogen, hydroxy, cyano, nitro, C₁-6alkyl, C₃-7cycloalkyl, C₃-7cycloalkyloxy, haloC₁-6alkyl, C₁-6alkoxy, haloC₁-6alkoxy or C₁-6alkylthio;

20 R₃ is halogen, cyano, C₁-6alkyl, C₃-7cycloalkyl, C₃-7cycloalkyloxy, C₁-6alkoxy, C₁-6alkylthio, hydroxy, amino, mono- or di-C₁-6alkylamino, an N-linked 4 to 7 membered heterocyclic group, nitro, haloC₁-6alkyl, haloC₁-6alkoxy, aryl, arylC₁-6alkyl, arylC₁-6alkyloxy, arylC₁-6alkylthio or COOR₆, CONR₇R₈ or COR₉ wherein R₆, R₇, R₈ and R₉ are independently hydrogen or C₁-6alkyl;

p is 0, 1 or 2 or 3;

25 R₄ is hydrogen, halogen, hydroxy, cyano, nitro, C₁-6alkyl, C₁-6alkanoyl, C₃-7cycloalkyl, C₃-7cycloalkyloxy, haloC₁-6alkyl, C₁-6alkoxy, haloC₁-6alkoxy, C₁-6alkylthio, amino, mono- or di-C₁-6alkylamino or an N-linked 4 to 7 membered heterocyclic group;

Y is oxygen, sulfur, -CH₂- or NR₁₀ wherein R₁₀ is hydrogen or C₁-6alkyl;


D is a single bond, -CH₂-, -(CH₂)₂- or -CH=CH-; and

Z is -NR₁₁R₁₂ where R₁₁ and R₁₂ are independently hydrogen or C₁-6alkyl, or an optionally substituted N-linked or C-linked 4 to 7 membered heterocyclic group.

30 2. A compound as claimed in claim 1, wherein X is -CH₂-.

35 3. A compound as claimed in claim 1 or claim 2, wherein when $\text{C}=\text{C}$ is a single bond, R₁ is hydrogen, hydroxy or C₁-6alkoxy.

4. A compound as claimed in claim 1 having the following formula (Ia):



- 5 wherein R_3 , p , R_4 , Y , D , Z , \equiv are as defined in claim 1, 2 or 3 and X_1 is $-\text{CH}_2-$ or $-\text{HC}(\text{OH})-$.

5. A compound as claimed in any of claims 1-4, wherein p is 1 or 2 and R_3 is/are halogen, particularly chloro or fluoro, attached at the 3 or the 3,4-positions of the phenyl ring.

6. A compound as claimed in any of claims 1-5, wherein R_4 is C_{1-6} alkoxy (particularly methoxy), OCF_3 , halogen or cyano.

7. A compound as claimed in any of claims 1-6, wherein D is $-\text{CH}_2-$.

8. A compound as claimed in any of claims 1-7, wherein Y is oxygen.

9. A compound as claimed in any of claims 1-8, wherein Z is an optionally substituted N-linked 4 to 7 membered heterocycle.

10. A compound as claimed in claim 9, wherein Z is piperidyl.

11. A compound as claimed in claim 1 which is:

1-(3,4-Dichloro-phenyl)-5-hydroxy-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-pyrrolidin-2-one

1-(3,4-Dichloro-phenyl)-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-1,5-dihydro-pyrrole-2-one

1-(3,4-Dichloro-phenyl)-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-pyrrolidin-2-one

1-(3,4-Dichloro-phenyl)-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-3-methyl-pyrrolidin-2-one

1-(4-Methoxyphenyl)-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-1,5-dihydro-pyrrole-2-one

1-(4-Methoxyphenyl)-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-pyrrolidin-2-one

1-(3-Chloro-4-methoxy-phenyl)-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-pyrrolidin-2-one

1-(3-Chloro-4-methoxy-phenyl)-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-1,5-dihydro-pyrrole-2-one

5 1-(3-Fluoro-4-methoxy-phenyl)-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-pyrrolidin-2-one

1-(3-Fluoro-4-methoxy-phenyl)-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-1,5-dihydro-pyrrole-2-one

1-(3-Fluoro-phenyl)-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-pyrrolidin-2-one


10 1-(3-Fluoro-phenyl)-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-1,5-dihydro-pyrrole-2-one

1-(3,4-Dichloro-phenyl)-5,5-dimethyl-4-hydroxy-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-pyrrol-2-one

15 1-(3,4-Dichloro-phenyl)-5,5-dimethyl-4-hydroxy-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-pyrrol-2-one or a pharmaceutically acceptable salt thereof.


12. A process for the preparation of a compound as defined in any of claims 1-11, which process comprises:

20 (a) reacting a compound of formula (II):




wherein R_1 , R_2 , R_3 , R_4 , m , p , X , \equiv , Y and D are as defined for formula (I), and L is a leaving group, with a compound of formula (III):

25



wherein Z is as defined for formula (I); or

30



(b) cyclising a compound of formula (IV):

- 5 wherein R_1 , R_2 , m , R_3 , p , R_4 , Y , D , Z and \equiv are as defined for formula (I) and G is a group $-X=CH_2$, wherein X is as defined for formula (I), dehydrogenated as required;

and thereafter, for either process (a) or process (b), optionally followed by:

- removing any protecting groups; and/or
- 10 • converting a compound of formula (I) into another compound of formula (I); and/or
- forming a pharmaceutically acceptable salt.

13. A pharmaceutical composition comprising a compound as defined in any of claims 1-14 and a pharmaceutically acceptable carrier or excipient.

15

14. A process for preparing a pharmaceutical composition as defined in claim 13, the process comprising mixing a compound a compound as defined in any of claims 1-14 and a pharmaceutically acceptable carrier or excipient.

20

15. A compound as defined in any of claims 1-11 for use as a therapeutic substance.

16. A compound as defined in any of claims 1-11 for use in the treatment of a CNS disorder.

25

17. A compound as defined in any of claims 1-11 for use in the treatment of depression or anxiety.

30

18. A method of treatment of CNS disorder in a mammal including a human, which comprises administering to the sufferer a therapeutically safe and effective amount of a compound as defined in any of claims 1-11.

35

19. A method of treatment of depression or anxiety in a mammal including a human, which comprises administering to the sufferer a therapeutically safe and effective amount of a compound as defined in any of claims 1-11.

20. Use of a compound as defined in any of claims 1-11 in the manufacture of a medicament for use in the treatment of a CNS disorder.

21. The use of a compound as defined in any of claims 1-11 in the manufacture of a medicament for use in the treatment of depression or anxiety.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2004/001843

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D207/26 C07D207/38 A61K31/40

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, EMBASE, BIOSIS, WPI Data, CHEM ABS Data, BEILSTEIN Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y A,P	WO 01/96308 A (RIVERS LEANNE ; SMITH TERENCE (GB); GROOM ANTHONY JOHN (GB); HATAKEYAMA) 20 December 2001 (2001-12-20) abstract; tables - & EP 1 300 396 A (EISAI CO LTD) 9 April 2003 (2003-04-09) claims; example 247 -----	1-21
Y A,P	WO 97/48700 A (BROMIDGE STEVEN MARK ; SMITHKLINE BEECHAM PLC (GB)) 24 December 1997 (1997-12-24) cited in the application abstract; claims ----- WO 03/089409 A (GLAXO GROUP LTD ; JAXA-CHAMIEC ALBERT ANDRZEJ (IT); DAMIANI FEDERICA () 30 October 2003 (2003-10-30) ----- -/-	1-21

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

° Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * & * document member of the same patent family

Date of the actual completion of the international search

22 July 2004

Date of mailing of the international search report

30/07/2004

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Frelon, D

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP2004/001843

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A, P	<p>WO 03/057220 A (GOODACRE CAROLINE ; LOVELL PETER JOHN (GB); GLAXO GROUP LTD (GB); BROM) 17 July 2003 (2003-07-17)</p> <p>-----</p>	

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP2004/001843

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: —
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 18 and 19 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP2004/001843

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0196308	A	20-12-2001	AU 6272301 A BR 0111596 A CA 2412172 A1 CN 1436172 T EP 1300396 A1 HU 0303398 A2 WO 0196308 A1 NO 20025955 A US 2004023973 A1	24-12-2001 02-03-2004 06-12-2002 13-08-2003 09-04-2003 01-03-2004 20-12-2001 12-02-2003 05-02-2004
EP 1300396	A	09-04-2003	AU 6272301 A BR 0111596 A CA 2412172 A1 CN 1436172 T EP 1300396 A1 HU 0303398 A2 WO 0196308 A1 NO 20025955 A US 2004023973 A1	24-12-2001 02-03-2004 06-12-2002 13-08-2003 09-04-2003 01-03-2004 20-12-2001 12-02-2003 05-02-2004
WO 9748700	A	24-12-1997	AT 196766 T AU 718000 B2 AU 3339697 A BR 9709982 A CA 2258559 A1 CZ 9804204 A3 DE 69703242 D1 DE 69703242 T2 DK 912556 T3 WO 9748700 A1 EP 0912556 A1 ES 2152682 T3 GR 3034847 T3 HK 1019744 A1 HU 9903480 A2 IL 127304 A JP 2000512644 T KR 2000022044 A NO 985970 A NZ 332840 A PL 330708 A1 PT 912556 T SI 912556 T1 TR 9802552 T2 US 6313145 B1 US 2002035134 A1 ZA 9705416 A	15-10-2000 06-04-2000 07-01-1998 10-08-1999 24-12-1997 12-05-1999 09-11-2000 08-03-2001 22-01-2001 24-12-1997 06-05-1999 01-02-2001 28-02-2001 15-03-2002 28-07-2000 06-07-2003 26-09-2000 25-04-2000 18-12-1998 26-05-2000 24-05-1999 28-02-2001 28-02-2001 22-02-1999 06-11-2001 21-03-2002 25-01-1999
WO 03089409	A	30-10-2003	WO 03089409 A1	30-10-2003
WO 03057220	A	17-07-2003	WO 03057220 A1	17-07-2003

REVISED VERSION

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
16 September 2004 (16.09.2004)

PCT

(10) International Publication Number
WO 2004/078718 A1

(51) International Patent Classification⁷: **C07D 207/26**,
207/38, A61K 31/40

(21) International Application Number:
PCT/EP2004/001843

(22) International Filing Date: 24 February 2004 (24.02.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0305024.2 5 March 2003 (05.03.2003) GB

(71) Applicant (for all designated States except US): **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DAMIANI, Federica** [IT/IT]; GlaxoSmithkline, Via Alessandro Fleming 2, I-37135 Verona (IT). **HAMPRECHT, Dieter** [DE/IT]; GlaxoSmithkline, Via Alessandro Fleming 2, I-37135 Verona (IT). **MICHEL, Fabrizio** [IT/IT]; GlaxoSmithkline, Via Alessandro Fleming 2, I-37135 Verona (IT). **PASQUARELLO, Alessandra** [IT/IT]; GlaxoSmithkline, Via Alessandro Fleming 2, I-37135 Verona (IT). **TEDESCO, Giovanna** [IT/IT]; GlaxoSmithkline, Via Alessandro Fleming 2, I-37135 Verona (IT).

(74) Agent: **KONDO, Rie**; GlaxoSmithkline, CIP (CN925.1), 980 Great West Road, Brentford, Middlesex TW8 9GS (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:


— with international search report

(88) Date of publication of the revised international search report: 26 May 2005

(15) Information about Correction:
see PCT Gazette No. 21/2005 of 26 May 2005, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMPOUNDS HAVING ACTIVITY AT 5HT_{2C} RECEPTOR AND USES THEREOF



(57) Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof are disclosed, wherein R₁ is hydrogen, fluoro, chloro, hydroxy, C₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyloxy, C₁₋₆alkoxy or haloC₁₋₆alkoxy; m is 0 when == is a double bond and m is 1 when == is a single bond; R₂ is hydrogen, halogen, cyano, nitro, C₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyloxy, haloC₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkoxy, C₁₋₆alkylthio,

amino, mono- or di-C₁₋₆alkylamino or an N-linked 4 to 7 membered heterocyclic group; X is -(CH₂-CH₂)-, -(CH=CH)-, -(CH₂)₃-, -C(CH₃)₂-, -(CH=CH-CH₂)-, -(CH₂-CH=CH)- or a group -(CHR₅)- wherein R₅ is hydrogen, halogen, hydroxy, cyano, nitro, C₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyloxy, haloC₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkoxy or C₁₋₆alkylthio; R₃ is halogen, cyano, C₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyloxy, C₁₋₆alkoxy, C₁₋₆alkylthio, hydroxy, amino, mono- or di-C₁₋₆alkylamino, an N-linked 4 to 7 membered heterocyclic group, nitro, haloC₁₋₆alkyl, haloC₁₋₆alkoxy, aryl, arylC₁₋₆alkyl, arylC₁₋₆alkyloxy, arylC₁₋₆alkylthio or COOR₆, CONR₇R₈ or COR₉ wherein R₆, R₇, R₈ and R₉ are independently hydrogen or C₁₋₆alkyl; p is 0, 1 or 2 or 3; R₄ is hydrogen, halogen, hydroxy, cyano, nitro, C₁₋₆alkyl, C₁₋₆alkanoyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyloxy, haloC₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkoxy, C₁₋₆alkylthio, amino, mono- or di-C₁₋₆alkylamino or an N-linked 4 to 7 membered heterocyclic group; Y is oxygen, sulfur, -CH₂- or NR₁₀ wherein R₁₀ is hydrogen or C₁₋₆alkyl; D is a single bond, -CH₂-, -(CH₂)₂- or -CH=CH-; and Z is -NR₁₁R₁₂ where R₁₁ and R₁₂ are independently hydrogen or C₁₋₆alkyl, or an optionally substituted N-linked or C-linked 4 to 7 membered heterocyclic group. Method of preparation and uses of the compounds in therapy, for example depression and anxiety, are also disclosed.

WO 2004/078718 A1

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP2004/001843

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D207/26 C07D207/38 A61K31/40

corrected version

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, EMBASE, BIOSIS, WPI Data, CHEM ABS Data, BEILSTEIN Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 01/96308 A (RIVERS LEANNE ; SMITH TERENCE (GB); GROOM ANTHONY JOHN (GB); HATAKEYAMA) 20 December 2001 (2001-12-20) abstract; tables	1-21
A, P	-8 EP 1 300 396 A (EISAI CO LTD) 9 April 2003 (2003-04-09) claims; example 247	
Y	WO 97/48700 A (BROMIDGE STEVEN MARK ; SMITHKLINE BEECHAM PLC (GB)) 24 December 1997 (1997-12-24) cited in the application abstract; claims	1-21
A, P	WO 03/089409 A (GLAXO GROUP LTD ; JAXA-CHAMIEC ALBERT ANDRZEJ (IT); DAMIANI FEDERICA ()) 30 October 2003 (2003-10-30)	

-/-

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

Date of the actual completion of the international search

22 July 2004

Date of mailing of the international search report

11. 02. 2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2250 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Frelon, D

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP2004/001843

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A,P	<p>WO 03/057220 A (GOODACRE CAROLINE ; LOVELL PETER JOHN (GB); GLAXO GROUP LTD (GB); BROM) 17 July 2003 (2003-07-17) -----</p>	

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP2004/001843

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 18 and 19 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP2004/001843

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0196308	A	20-12-2001	AU 6272301 A	24-12-2001
			BR 0111596 A	02-03-2004
			CA 2412172 A1	06-12-2002
			CN 1436172 T	13-08-2003
			EP 1300396 A1	09-04-2003
			HU 0303398 A2	01-03-2004
			WO 0196308 A1	20-12-2001
			NO 20025955 A	12-02-2003
			US 2004023973 A1	05-02-2004

EP 1300396	A	09-04-2003	AU 6272301 A	24-12-2001
			BR 0111596 A	02-03-2004
			CA 2412172 A1	06-12-2002
			CN 1436172 T	13-08-2003
			EP 1300396 A1	09-04-2003
			HU 0303398 A2	01-03-2004
			WO 0196308 A1	20-12-2001
			NO 20025955 A	12-02-2003
			US 2004023973 A1	05-02-2004

WO 9748700	A	24-12-1997	AT 196766 T	15-10-2000
			AU 718000 B2	06-04-2000
			AU 3339697 A	07-01-1998
			BR 9709982 A	10-08-1999
			CA 2258559 A1	24-12-1997
			CZ 9804204 A3	12-05-1999
			DE 69703242 D1	09-11-2000
			DE 69703242 T2	08-03-2001
			DK 912556 T3	22-01-2001
			WO 9748700 A1	24-12-1997
			EP 0912556 A1	06-05-1999
			ES 2152682 T3	01-02-2001
			GR 3034847 T3	28-02-2001
			HK 1019744 A1	15-03-2002
			HU 9903480 A2	28-07-2000
			IL 127304 A	06-07-2003
			JP 2000512644 T	26-09-2000
			KR 2000022044 A	25-04-2000
			NO 985970 A	18-12-1998
			NZ 332840 A	26-05-2000
			PL 330708 A1	24-05-1999
			PT 912556 T	28-02-2001
			SI 912556 T1	28-02-2001
			TR 9802552 T2	22-02-1999
			US 6313145 B1	06-11-2001
			US 2002035134 A1	21-03-2002
			ZA 9705416 A	25-01-1999

WO 03089409	A	30-10-2003	WO 03089409 A1	30-10-2003
			EP 1497265 A1	19-01-2005

WO 03057220	A	17-07-2003	AU 2003201636 A1	24-07-2003
			EP 1465630 A1	13-10-2004
			WO 03057220 A1	17-07-2003
